Overall, these data show that inhibiting tumor-NLRP3 alone is sufficient to reduce IL-6/STAT3 activation, resulting in the reduction of immunosuppressive gene expression in PMN-MDSCs. The gene discussed is IL6; the disease is neoplasm.